Plain-English translation of NCT07195799 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing linperlisib combined with a three-drug chemotherapy regimen (cyclophosphamide, prednisone, and thalidomide) in people whose non-Hodgkin lymphoma has come back or stopped responding to earlier treatments. Researchers want to see if adding this new medication to the standard chemotherapy combination can help control the disease better and for longer. This study includes people with several different types of lymphoma that have proven difficult to treat.
Many patients with lymphoma eventually develop disease that no longer responds to standard treatments, and their options become very limited. This trial is exploring whether this medication could offer a new way to fight back against these hard-to-treat forms of lymphoma when other options have failed.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication (linperlisib) along with the three chemotherapy drugs, likely through infusions or pills taken at scheduled intervals. You'll have regular clinic visits for treatment administration, blood tests to monitor your health and how your body is responding, and imaging scans (like CT scans) to check whether the lymphoma is shrinking. The study will track your side effects and how well the treatment is working over time, with the goal of understanding whether this combination approach can help people whose lymphoma has become resistant to standard care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China